Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTC Benitec Biopharma	$14.57 -0.3%	$14.45	$6.66 ▼ $17.15	$383.52M	0.44	43,717 shs	218,113 shs
ELUT Elutia	$1.74 -3.9%	$1.94	$1.61 ▼ $5.24	$74.42M	0.86	46,365 shs	29,826 shs
PHAT Phathom Pharmaceuticals	$9.47 -9.1%	$5.32	$2.21 ▼ $19.71	$727.46M	0.08	1.51 million shs	3.42 million shs
RGNX REGENXBIO	$7.86 -6.8%	$8.78	$5.04 ▼ $15.36	$422.85M	1.09	922,352 shs	939,879 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTC Benitec Biopharma	-0.27%	-7.49%	+10.46%	-0.68%	+111.77%
ELUT Elutia	-3.87%	-1.14%	+1.16%	-36.50%	-50.29%
PHAT Phathom Pharmaceuticals	-9.12%	-11.00%	+135.57%	+48.20%	-14.53%
RGNX REGENXBIO	-6.76%	-14.19%	-19.05%	-4.26%	-34.61%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BNTC Benitec Biopharma	2.5393 of 5 stars	3.6	2.0	0.0	2.9	2.5	0.0
ELUT Elutia	3.18 of 5 stars	3.5	5.0	0.0	0.6	3.3	0.6
PHAT Phathom Pharmaceuticals	3.9379 of 5 stars	4.5	2.0	0.0	2.4	5.0	0.6
RGNX REGENXBIO	4.3435 of 5 stars	3.4	2.0	4.6	2.7	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BNTC Benitec Biopharma	3.22	Buy	$23.83	63.58% Upside
ELUT Elutia	3.00	Buy	$8.00	359.77% Upside
PHAT Phathom Pharmaceuticals	3.00	Buy	$17.50	84.79% Upside
RGNX REGENXBIO	2.83	Moderate Buy	$31.63	302.35% Upside

Current Analyst Ratings Breakdown

Latest ELUT, PHAT, RGNX, and BNTC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/9/2025	PHAT Phathom Pharmaceuticals	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$12.00 ➝ $17.00
6/9/2025	PHAT Phathom Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/9/2025	RGNX REGENXBIO	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$52.00
6/6/2025	PHAT Phathom Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00
5/19/2025	BNTC Benitec Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00
5/15/2025	BNTC Benitec Biopharma	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$20.00 ➝ $20.00
5/9/2025	ELUT Elutia	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$10.00 ➝ $8.00
5/2/2025	PHAT Phathom Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$10.00 ➝ $5.00
5/2/2025	PHAT Phathom Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$18.00 ➝ $12.00
5/2/2025	PHAT Phathom Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $20.00
4/21/2025	PHAT Phathom Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00

(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BNTC Benitec Biopharma	$80K	4,780.78	N/A	N/A	$4.68 per share	3.11
ELUT Elutia	$24.38M	2.93	N/A	N/A	($1.31) per share	-1.33
PHAT Phathom Pharmaceuticals	$55.25M	11.97	N/A	N/A	($3.71) per share	-2.55
RGNX REGENXBIO	$83.33M	4.73	N/A	N/A	$5.24 per share	1.50

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BNTC Benitec Biopharma	-$21.75M	-$1.51	N/A	N/A	N/A	N/A	-38.26%	-35.71%	N/A
ELUT Elutia	-$53.95M	-$1.93	N/A	N/A	N/A	-168.23%	N/A	-96.70%	7/28/2025 (Estimated)
PHAT Phathom Pharmaceuticals	-$334.33M	-$5.24	N/A	N/A	N/A	-422.42%	N/A	-90.11%	8/6/2025 (Estimated)
RGNX REGENXBIO	-$227.10M	-$3.11	N/A	N/A	N/A	-100.62%	-53.29%	-30.84%	8/7/2025 (Estimated)

Latest ELUT, PHAT, RGNX, and BNTC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q3 2025	BNTC Benitec Biopharma	-$0.36	-$0.24	+$0.12	-$0.24	N/A	N/A
5/12/2025	Q1 2025	RGNX REGENXBIO	$0.41	$0.12	-$0.29	$0.12	$105.35 million	$89.01 million
5/8/2025	Q1 2025	ELUT Elutia	-$0.20	-$0.21	-$0.01	-$0.21	$6.65 million	$6.03 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BNTC Benitec Biopharma	N/A	N/A	N/A	N/A	N/A
ELUT Elutia	N/A	N/A	N/A	N/A	N/A
PHAT Phathom Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RGNX REGENXBIO	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BNTC Benitec Biopharma	0.01	14.80	14.80
ELUT Elutia	N/A	0.81	0.70
PHAT Phathom Pharmaceuticals	N/A	3.58	3.54
RGNX REGENXBIO	N/A	2.93	2.93

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BNTC Benitec Biopharma	52.19%
ELUT Elutia	74.03%
PHAT Phathom Pharmaceuticals	99.01%
RGNX REGENXBIO	88.08%

Insider Ownership

Company	Insider Ownership
BNTC Benitec Biopharma	1.30%
ELUT Elutia	27.60%
PHAT Phathom Pharmaceuticals	24.10%
RGNX REGENXBIO	12.79%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BNTC Benitec Biopharma	20	26.25 million	25.91 million	No Data
ELUT Elutia	180	41.12 million	29.77 million	Not Optionable
PHAT Phathom Pharmaceuticals	110	69.81 million	52.99 million	Optionable
RGNX REGENXBIO	370	50.16 million	43.75 million	Optionable

ELUT, PHAT, RGNX, and BNTC Headlines

Recent News About These Companies

Assenagon Asset Management S.A. Sells 283,399 Shares of REGENXBIO Inc. (NASDAQ:RGNX)

June 16, 2025 | marketbeat.com

REGENXBIO (NASDAQ:RGNX) Stock Price Up 6.1% - What's Next?

June 11, 2025 | marketbeat.com

A Glimpse Into The Expert Outlook On Regenxbio Through 8 Analysts

June 9, 2025 | benzinga.com

REGENXBIO's (RGNX) Buy Rating Reaffirmed at Chardan Capital

June 9, 2025 | marketbeat.com

Regenxbio's RGX-121 Could Become The New Standard Of Care In Hunter Syndrome

June 6, 2025 | seekingalpha.com

Otsuka tops Vera with kidney drug data; Regenxbio sinks on Duchenne update

June 6, 2025 | biopharmadive.com

RegeNXBio shares fall, despite positive new data on RGX-202

June 6, 2025 | thepharmaletter.com

Regenxbio’s Duchenne gene therapy data positive as shares falter

June 5, 2025 | bioworld.com

Regenxbio Fails To Best Sarepta’s Elevidys With New Data for DMD Gene Therapy

June 5, 2025 | biospace.com

REGENXBIO updates Phase 1/2 data for Duchenne candidate

June 5, 2025 | msn.com

Early Wins: RegenXBio's Gene Therapy Helps Duchenne Patients Walk Stronger, Longer

June 5, 2025 | benzinga.com

REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202

June 5, 2025 | prnewswire.com

REGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Recommendation of "Moderate Buy" by Brokerages

June 5, 2025 | marketbeat.com

REGENXBIO (NASDAQ:RGNX) Shares Up 13.5% - Still a Buy?

June 3, 2025 | marketbeat.com

Short Interest in REGENXBIO Inc. (NASDAQ:RGNX) Expands By 21.9%

June 3, 2025 | marketbeat.com

Bank of America Corp DE Reduces Stock Holdings in REGENXBIO Inc. (NASDAQ:RGNX)

June 3, 2025 | marketbeat.com

REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202

June 2, 2025 | prnewswire.com

Two Sigma Advisers LP Acquires 112,000 Shares of REGENXBIO Inc. (NASDAQ:RGNX)

June 1, 2025 | marketbeat.com

Two Sigma Investments LP Acquires 263,495 Shares of REGENXBIO Inc. (NASDAQ:RGNX)

June 1, 2025 | marketbeat.com

FY2026 EPS Estimates for REGENXBIO Increased by Analyst

May 31, 2025 | marketbeat.com

Millennium Management LLC Buys 1,061,187 Shares of REGENXBIO Inc. (NASDAQ:RGNX)

May 26, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELUT, PHAT, RGNX, and BNTC Company Descriptions

Benitec Biopharma NASDAQ:BNTC

$14.57 -0.04 (-0.27%)

Closing price 06/23/2025 04:00 PM Eastern

Extended Trading

$14.60 +0.03 (+0.21%)

As of 06/23/2025 05:53 PM Eastern

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

Elutia NASDAQ:ELUT

$1.74 -0.07 (-3.87%)

Closing price 06/23/2025 04:00 PM Eastern

Extended Trading

$1.74 0.00 (0.00%)

As of 06/23/2025 04:04 PM Eastern

Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.

Phathom Pharmaceuticals NASDAQ:PHAT

$9.47 -0.95 (-9.12%)

Closing price 06/23/2025 04:00 PM Eastern

Extended Trading

$9.55 +0.08 (+0.89%)

As of 06:36 AM Eastern

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

REGENXBIO NASDAQ:RGNX

$7.86 -0.57 (-6.76%)

Closing price 06/23/2025 04:00 PM Eastern

Extended Trading

$8.30 +0.44 (+5.60%)

As of 06:50 AM Eastern

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time